Ruserontinib

Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity[1].

Product Specifications

CAS Number

[1350544-93-2]

Product Name Alternative

SKLB1028

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bcr-Abl; EGFR; FLT3

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ruserontinib.html

Purity

99.32

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C4N=C(N(C4=N3)C(C)C)NC5=CC=CN=C5

Molecular Formula

C24H29N9

Molecular Weight

443.55

Precautions

H302, H315, H319, H335

References & Citations

[1]Z-X Cao, et al. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia. 2012 Aug;26 (8) :1892-5.